Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982;78(1):81-4.
doi: 10.1007/BF00470594.

The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy

The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy

M Globus et al. Psychopharmacology (Berl). 1982.

Abstract

Chronic treatment with dopamine (DA) agonists has been reported in various paradigms to cause supersensitivity of DA receptors or, contradictorily, subsensitivity of DA receptors. The present study administered 15 mg/kg bromocriptine for 7 days and measured both striatal spiperone binding and apomorphine (AP)-induced stereotypy. A significant decrease in AP-induced stereotypies was observed after chronic bromocriptine treatment, but without a significant parallel decrease in striatal spiperone binding. These results probably do not represent a true agonist-induced subsensitivity, but possibly show that residual bromocriptine in vivo may antagonize AP-induced stereotypy. Since some reports have suggested that L-Dopa may specifically reverse the increases in DA receptor number induced by chronic haloperidol, we also studied the effect of 7 days of L-Dopa treatment after 6-week chronic haloperidol treatment of mice. While chronic haloperidol significantly increased striatal spiperone binding, subsequent L-Dopa treatment did not reverse this biochemical supersensitivity. It is concluded that agonist induction of subsensitivity in the DA system is difficult to reproduce and may depend on highly specific dosage conditions and treatment schedules.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Psychopharmacologia. 1971;21(2):131-8 - PubMed
    1. Arch Gen Psychiatry. 1975 Jun;32(6):725-32 - PubMed
    1. Psychopharmacology (Berl). 1981;75(2):169-72 - PubMed
    1. Pharmacol Biochem Behav. 1974 Mar-Apr;2(2):249-55 - PubMed
    1. Res Commun Chem Pathol Pharmacol. 1977 Mar;16(3):411-23 - PubMed

Publication types

LinkOut - more resources